Quan Joanne

CMO Quan Joanne sold 7,287 shares of MIRM at $91.98, reducing stake by 27.9% to 18,864 shares post-transaction

Quan Joanne, Chief Medical Officer at Mirum Pharmaceuticals, sold 7,287 shares (27.9% of her pre-transaction holdings of 26,151 shares) at $91.98 on 2026-03-16, totaling $670,242.96. The stock currently trades at $96.55, placing the transaction price 5.1% below the current market level and 11.1% below the 52-week high of $108.62. The company shows strong quarterly revenue of $133,010,000.00 and annual growth of +54.7%, but trades at a notably elevated P/E of 254.08 and was unprofitable over its most recent full fiscal year. While Quan's cross-ticker track record shows 1 prior sell with an average 30-day return of +16.9%, this represents limited historical context. The sale occurs within a volatile 90-day window where the stock is up +39.9% but down 6.4% over the last 30 days, creating a mixed technical signal that requires monitoring given the executive's significant role in a biotech company's operations.

CMO Quan Joanne sold 6,911 shares of MIRM at $90.27 (-37.9% of holdings); stock now at $93.27 on +80.8% annual revenue growth.

Quan Joanne, Chief Medical Officer, sold 6,911 shares (6.9K shares) at $90.27, reducing her position from 18,216 shares (18.2K shares) to 11,305 shares (11.3K shares)—a reduction of 37.9% of her prior holdings. The transaction occurred just $3.00 below the current price of $93.27, placing it near the 52-week high of $93.27. Mirum Pharmaceuticals showed strong fundamentals with 80.8% annual revenue growth and $133.0M in latest-quarter revenue, though the company remains unprofitable on a full-year basis with net income of $2.9M in the latest quarter but negative full-year results. The stock has appreciated 15.0% over the past 30 days and 34.4% over the past 90 days, reflecting strong recent momentum.